ソービーは2億7500万ドルを支払って アスパヴェリ社のロイヤリティを90%削減し 希少腎臓疾患の承認を 資金提供しています Sobi pays $275M to cut Aspaveli royalties by 90%, funding rare kidney disease approvals in EU.

ソビとアペリス製薬は アスパヴェリのライセンス契約を修正し, ソビの元米国ロイヤリティの義務を90%削減しました. 支払額は2億7500万ドル,マイルストーン支払いは最大2千5百万ドル. Sobi and Apellis Pharmaceuticals have amended their licensing agreement for Aspaveli, reducing Sobi's ex-US royalty obligations by 90% in exchange for a $275 million upfront payment and up to $25 million in milestone payments. EUに出資した取引資金は,稀な腎臓疾患C3GとIC-MPGNに係る. The deal funds regulatory approvals in the EU for rare kidney diseases C3G and IC-MPGN. AspaviliはすでにEUと米国でPNHの治療を承認しており,この新たな指標の見直しが継続している. Aspaveli is already approved in the EU and US for treating PNH, with reviews ongoing for the new indications.